<DOC>
	<DOCNO>NCT01004003</DOCNO>
	<brief_summary>The study aim determine maximally tolerate dose ( MTD ) BIBF 1120 HCC ( hepatocellular cancer ) compare efficacy BIBF 1120 Sorafenib HCC patient</brief_summary>
	<brief_title>Phase I/II Comparison Efficacy Safety BIBF 1120 Sorafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis hepatocellular carcinoma ( HCC ) amenable tocurative surgery locoregional therapy ( RFA , PEI , TACE ) Age 18 year old Eastern Cooperative Oncology Group performance score 2 less ChildPugh score A ( score 56 ) At least one measurable lesion accord RECIST 1.0 ( criterion limit phase II ) In case measurable lesion previously treat locoregional therapy ( RFA , PEI , TACE RT ) , lesion must document progression accord RECIST 1.0 CT MRI ( criterion limit phase II ) . Time interval last local therapy ( e.g . radiofrequency ablation , percutaneous ethanol injection , radiotherapy , transarterial chemoembolization ) 4 week prior start study treatment Written inform consent consistent International Conference Harmonisation/ Good Clinical Practice ( ICHGCP ) local legislation Exclusion criterion : Prior systemic therapy HCC Fibrolamellar hepatocellular carcinmoa ( HCC ) Bilirubin great 1.5 time ULN AST ALT great 2 time ULN Uncontrolled refractory ascites adequate medical therapy Hepatic encephalopathy grade 1 accord ChildPugh criterion Prothrombin time international normalize ratio great 2.3 , prothrombin time 6 second prolong control Absolute neutrophil count less 1000 /µL Platelet count le 60000 /µL Hemoglobin le 9 g/dL Serum creatinine great 1.5 time Upper Limit Normal ( ULN ) Proteinuria Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 great Variceal bleeding within last 6 month prior start study treatment History major thrombotic ( except portal vein thrombosis ) clinically relevant major bleed event past 6 month Known inherited predisposition bleed thrombosis Significant cardiovascular disease ( i.e . hypertension control medical therapy , blood pressure &gt; 150/90 mmHg ) , unstable angina , history myocardial infarction within past 6 month , congestive heart failure &gt; class II accord New York Heart Association ( NYHA ) , serious cardiac arrhythmia , pericardial effusion ) Therapeutic anticoagulation ( except low dose heparin and/or heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose therapy acetylsalicylic acid = &lt; 325mg per day ) Major surgery within 4 week prior start study treatment Treatment investigational drug participation another clinical trial within past four week start therapy concomitantly trial ( except present trial drug ) Known serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study Patients sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner participate female , condom participate male ) trial least twelve month end active therapy Current alcohol abuse drug abuse would limit pt ability comply protocol Symptomatic central nervous system ( CNS ) metastasis Life expectancy le 12 week Patient unable take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>